Clinical Efficacy of Solifenacin in the Management of Diabetes Mellitus-Associated Versus Idiopathic Overactive Bladder Symptoms: A Multicenter Prospective Study

Overactive Bladder

Long-term Safety and Efficacy of Mirabegron and Solifenacin in Combination Compared with Monotherapy in Patients with Overactive Bladder: A Randomised, Multicentre Phase 3 Study (SYNERGY II)

Eur Urol.

Gratzke C, van Maanen R, Chapple C, Abrams P, Herschorn S, Robinson D, Ridder A, Stoelzel M, Paireddy A, Yoon SJ, Al-Shukri S, Rechberger T, Mueller ER

doi: 10.1016/j.eururo.

Lower Urinary Tract SymptomsOveractive Bladder

Safety, Efficacy, and Persistence of Long-Term Mirabegron Treatment for Overactive Bladder in the Daily Clinical Setting: Interim (1-Year) Report from a Japanese Post-Marketing Surveillance Study

Low Urin Tract Symptoms.

Kato D, Tabuchi H, Uno S

doi: 10.1111/luts.12188.

Benign Prostatic Hyperplasia (BPH)Overactive Bladder

Efficacy and Safety of Mirabegron versus Placebo Add-On Therapy in Men with Overactive Bladder Symptoms Receiving Tamsulosin for Underlying Benign Prostatic Hyperplasia: A Randomized, Phase 4 Study (PLUS)

J Urol.

Kaplan SA, Herschorn S, McVary KT, Staskin D, Chapple C, Foley S, Cambronero Santos J, Kristy RM, Choudhury N, Hairston J, Schermer CR

doi: 10.1097/JU.0000000000000738.

Overactive Bladder

Safety and Efficacy of Mirabegron: Analysis of a Large Integrated Clinical Trial Database of Patients with Overactive Bladder Receiving Mirabegron, Antimuscarinics, or Placebo

Eur Urol.

Chapple CR, Cruz F, Cardozo L, Staskin D, Herschorn S, Choudhury N, Stoelzel M, Heesakkers J, Siddiqui E

doi: 10.1016/j.eururo.2019.09.024.

Overactive BladderUrinary Incontinence

Efficacy and tolerability of treatment with mirabegron compared with solifenacin in the management of overactive bladder syndrome: A retrospective analysis

J Obstet Gynaecol Res.

Schiavi MC, Faiano P, D'Oria O, Zullo MA, Muzii L, Benedetti Panici P

doi: 10.1111/jog.13541.

Overactive Bladder

Persistence and Adherence with Mirabegron versus Antimuscarinic Agents in Patients with Overactive Bladder: A Retrospective Observational Study in UK Clinical Practice

Eur Urol.

Chapple CR, Nazir J, Hakimi Z, Bowditch S, Fatoye F, Guelfucci F, Khemiri A, Siddiqui E, Wagg A

doi: 10.1016/j.eururo.2017.01.037.

Overactive Bladder

Effectiveness and durability of solifenacin versus percutaneous tibial nerve stimulation versus their combination for the treatment of women with overactive bladder syndrome: a randomized controlled study with a follow-up of ten months

Int Braz J Urol.

Vecchioli-Scaldazza C, Morosetti C

doi: 10.1590/

Overactive Bladder

Efficacy and Safety of Combination Pharmacotherapy for Patients with Overactive Bladder: A Rapid Evidence Assessment

Eur Urol.

Gratzke C, Chapple C, Mueller ER, Robinson D, Rolland C, Staskin D, Stoelzel M, Maanen RV, Siddiqui E

doi: 10.1016/j.eururo.2019.07.010.

Overactive BladderUrinary Incontinence

Comparative efficacy and tolerability of solifenacin 5 mg/day versus other oral antimuscarinic agents in overactive bladder: A systematic literature review and network meta-analysis

Neurourol Urodyn.

Nazir J, Kelleher C, Aballéa S, Maman K, Hakimi Z, Mankowski C, Odeyemi I

doi: 10.1002/nau.23413.

Related content

Long-term Safety and Efficacy of Mirabegron and Solifenacin in Combination Compared with Monotherapy in Patients with Overactive Bladder: A Randomised, Multicentre Phase 3 Study (SYNERGY II)

Safety, Efficacy, and Persistence of Long-Term Mirabegron Treatment for Overactive Bladder in the Daily Clinical Setting: Interim (1-Year) Report from a Japanese Post-Marketing Surveillance Study

Efficacy and Safety of Mirabegron versus Placebo Add-On Therapy in Men with Overactive Bladder Symptoms Receiving Tamsulosin for Underlying Benign Prostatic Hyperplasia: A Randomized, Phase 4 Study (PLUS)

Safety and Efficacy of Mirabegron: Analysis of a Large Integrated Clinical Trial Database of Patients with Overactive Bladder Receiving Mirabegron, Antimuscarinics, or Placebo

Efficacy and tolerability of treatment with mirabegron compared with solifenacin in the management of overactive bladder syndrome: A retrospective analysis

Persistence and Adherence with Mirabegron versus Antimuscarinic Agents in Patients with Overactive Bladder: A Retrospective Observational Study in UK Clinical Practice

Effectiveness and durability of solifenacin versus percutaneous tibial nerve stimulation versus their combination for the treatment of women with overactive bladder syndrome: a randomized controlled study with a follow-up of ten months

Efficacy and Safety of Combination Pharmacotherapy for Patients with Overactive Bladder: A Rapid Evidence Assessment

Comparative efficacy and tolerability of solifenacin 5 mg/day versus other oral antimuscarinic agents in overactive bladder: A systematic literature review and network meta-analysis